Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Mavelertinib |
Synonyms | |
Therapy Description |
Mavelertinib (PF-06747775) is a specific inhibitor of EGFR T790M, which causes cell death in EGFR T790M-positive tumor cells, while sparing wild-type EGFR (PMID: 30718357). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Mavelertinib | PF-06747775 | EGFR Inhibitor 3rd gen 26 | Mavelertinib (PF-06747775) is a specific inhibitor of EGFR T790M, which causes cell death in EGFR T790M-positive tumor cells, while sparing wild-type EGFR (PMID: 30718357). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02349633 | Phase II | Avelumab + Mavelertinib Mavelertinib + Palbociclib Mavelertinib | Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) | Terminated | USA | AUS | 2 |